NCT07288138

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Eccogene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

Conditions

• Metabolic Dysfunction-associated Steatohepatitis

Interventions

Type	Name	Description
DRUG	Placebo	Placebo will be administered as matching oral capsules.
DRUG	ECC4703	ECC4703 will be administered as oral capsules.
DRUG	ECC0509	ECC0509 will be administered as oral capsules.
DRUG	ECC4703	ECC4703 will be administered as oral capsules.

Timeline

• Start date: 2025-12-15
• Primary completion: 2026-10-16
• Completion: 2026-10-30
• First posted: 2025-12-17
• Last updated: 2026-03-16

Locations

39 sites across 1 country: United States

Regulatory

• FDA-regulated drug study